Down 25% in a month, the Incannex share price is now halted. Here's why

A key update awaits the market from Incannex.

| More on:
A dollar sign embedded in ice, indicating a share price freeze or trading halt

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Incannex Healthcare shares are on the backburner today pending a company announcement 
  • Prior to the halt they were resting at 38 cents apiece. The company intends to release readouts from a recent clinical trial 
  • In the last 12 months, the Incannex Healthcare share price has held a 24% gain 

Shares of Incannex Healthcare Ltd (ASX: IHL) are on ice today pending a company announcement. Before being placed on the backburner, the Incannex share price rested at 38 cents apiece.

Zooming out, shares of the cannabis player have faltered more than 39% this year to date, amid a violent selloff in growth-type shares in 2022.

In wider market moves, the S&P/ASX 200 Health Care Index (ASX: XHJ) has crumbled today and is now more than 3% in the red, bringing losses to 12% this year.

Meanwhile, in the US, the Nasdaq Composite Index (Nasdaq) fell sharply overnight, marking its largest single-day drop since 2020.

Investors sold off shares in the tech-biased Nasdaq after US Federal Reserve chair Jerome Powell raised the Fed's base interest rate by 0.5 percentage points, in an effort to control inflationary pressures.

Why is the Incannex share price halted?

The company requested its shares be put on ice in lieu of a market-sensitive announcement regarding upcoming study readouts.

"[Incannex] requests a trading halt to be applied to its securities…pending an announcement by the company regarding results of its extensive preclinical study assessing IHL-216A in a sports concussion model," it said in the filing.

"The Company requests that the trading halt remains in place until the earlier of the commencement of normal trading on May 10, 2022 or the release of the announcement."

Naturally the ASX awarded Incannex its request and, as such, investors must now wait until the company posts its next update on or before May 10.

Earlier in the year, investors appeared rattled by Incannex's decision to acquire APIRx Pharmaceutical USA, LLC for US$93 million.

Even though it now claims a total addressable market of more than US$400 billion globally, investors didn't appear as thrilled.

As such, losses have continued into May and shares have stooped from a high of 70 cents in March.

Incannex Healthcare share price snapshot

In the last 12 months, the Incannex Healthcare share price has held a 24% gain. However, it has collapsed into the red on each of the shorter time frames.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why the Mesoblast share price is diving 18% after an FDA win

Investors are sending the Mesoblast share price tumbling on Friday. But why?

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Guess which ASX healthcare stock is jumping 12% on Wednesday

This shares is rocketing this morning. But why? Let's find out.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Healthcare Shares

Here is the dividend forecast to 2029 for CSL shares

Can this blue-chip giant provide healthy dividend income?

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

The best ASX 200 healthcare stocks to buy in 2025

These shares could give your portfolio a healthy boost next year according to Bell Potter.

Read more »

In the lab at work, the mature adult woman and young adult man smile as they review the results of their successful experimentation.
Healthcare Shares

ASX 300 healthcare stock lifts off on promising new results

Up 28% in a year, the ASX healthcare stock is leaping higher on Thursday.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

If you'd invested $5,000 in this ASX 300 healthcare stock a year ago, you'd now have $30,000!

This stock has made millions for investors over just a few months.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

Has the Pro Medicus share price risen too high too quickly?

Pro Medicus shares have rocketed 173% since this time last year.

Read more »